Eli Lilly: new recommended dosage for Kisunla

Published: 2025-07-09 08:29:18 ET LLY

Published on 07/09/2025 at 08:29

Eli Lilly has announced that the US FDA has approved a label update with a new recommended dosing regimen for Kisunla, its bimonthly treatment for adults with early symptomatic Alzheimer's disease.The new recommended regimen has significantly reduced rates of ARIA-E (amyloid imaging abnormalities with edema/effusion) compared to the initial dosing regimen, further strengthening the treatment's established safety profile.By significantly reducing the risk of ARIA-E, we can offer patients and caregivers greater confidence in the safety of Kisunla while maintaining its ability to reduce amyloid, the Irvine Center for Clinical Research said. Copyright (c) 2025 CercleFinance.com - All rights reserved.